Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects
Pfizer said it still plans to release phase two trial data on a once-a-day version of its weight loss drug, known as danuglipron, in the first half of 2024.
Similar Posts
Trip.com Q3 2023 Earnings Preview
Post Content Post Views: 130
Fed Chair Powell calls talk of cutting rates ‘premature’ and says more hikes could happen
Federal Reserve Chairman Jerome Powell on Friday pushed back on market expectations for aggressive interest rate cuts ahead. Post Views: 118
ATF prices slashed by 4.6% as India’s oil companies update monthly rates
Post Content Post Views: 122
ADX and FTSE Russell launch new ESG index ahead of COP28 summit
Post Content Post Views: 107
UK regulator advocates for asset managers to tokenize funds
Post Content Post Views: 147
Pfizer’s twice-daily weight loss pill joins a long list of obesity drug flops
Before successful weight loss treatments such as Wegovy and Ozempic, the pharmaceutical path to treating obesity was strewn with failures dating back decades. Post Views: 116